Drug
GLS4
GLS4 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
NCT04147208
completedphase_1
GLS4/RTV and TAF Drug-drug Interaction
NCT04551261
completedphase_2
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
NCT03638076
completedphase_1
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
NCT03662568
Clinical Trials (4)
Showing 4 of 4 trials
NCT04147208Phase 2
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
NCT04551261Phase 1
GLS4/RTV and TAF Drug-drug Interaction
NCT03638076Phase 2
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
NCT03662568Phase 1
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4